• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Diabetic Hypertension - Pipeline Review, H1 2012 Product Image

Diabetic Hypertension - Pipeline Review, H1 2012

  • Published: March 2012
  • 17 pages
  • Global Markets Direct

Diabetic Hypertension – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Diabetic Hypertension - Pipeline Review, H1 2012', provides an overview of the Diabetic Hypertension therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Hypertension. 'Diabetic Hypertension - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Diabetic Hypertension.
- A review of the Diabetic Hypertension products under development by companies READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diabetic Hypertension Overview
Therapeutics Development
An Overview of Pipeline Products for Diabetic Hypertension
Diabetic Hypertension Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Diabetic Hypertension Therapeutics – Products under Investigation by Universities/Institutes
Assessment by Combination Products
Assessment by Molecule Type
Drug Profiles
Candesartan/Valsartan + Amlodipine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diabetic Hypertension Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Diabetic Hypertension, H1 2012
Products under Development for Diabetic Hypertension – Comparative Analysis, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Diabetic Hypertension Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Diabetic Hypertension, H1 2012
Products under Development for Diabetic Hypertension – Comparative Analysis, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Mid Clinical Stage Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Site License The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.
Enterprisewide The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos